Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the ...

Inflammatix, a leader in host-response diagnostics, today announced that its TriVerity™ Test has been granted New Technology Add-On Payment (NTAP) reimbursement by the Centers for Medicare & Medicaid ...